skip to main content

Hybridize Therapeutics

Novel drug development laboratory

Hybridize Therapeutics is developing RNA therapeutics to treat kidney diseases. Current focus areas are the BK virus- and fibrosis programs. The BK-virus program aims to develop an antisense oligonucleotide therapy to supress virus expression after a kidney transplantation.

The company uses the Mibiton lease fund to equip the R&D laboratories.

Eric van der Veer, CIO & Founder

Eline Vrijland, CEO

"Thanks to the loan we received from Mibiton, we were able to fully equip our R&D laboratories. This has been instrumental in helping us execute our research efforts and bringing our programs closer to the clinic. We're grateful for the support and partnership of Mibiton in helping us achieve our goals."